EPISODE · Apr 4, 2024 · 28 MIN
Evolution of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma
from Keeping Current CME
Did you know that HER2-targeted therapy is an established treatment option for patients with HER2-positive metastatic gastric/gastroesophageal junction (GEJ) cancer? Credit available for this activity expires: 3/29/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000593?ecd=bdc_podcast_libsyn_mscpedu
Embed this episode
NOW PLAYING
Evolution of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma
0:00
28:57
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Keeping Current CME?
This episode is 28 minutes long.
When was this Keeping Current CME episode published?
This episode was published on April 4, 2024.
Can I download this Keeping Current CME episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!